News

Clearing the hurdles with exosomes

Could exosome therapy help athletes recover from injury faster – and help the rest of us by mimicking the whole-body benefits of exercise? Some people don’t get enough physical exercise – but others suffer from too much activity, injury and overtraining. Many sports...

read more

Turning back the body clock

New research reinforces the possibility that exosomes derived from stem cells can bring the body back in to a more healthful, youthful state. Two recent publications highlight the growing relevance of exosomes to aging. One report highlights that aging of humans is...

read more

Exosomes versus stem cells

The exosomes released by stem cells look a far more promising therapy than cells themselves for tackling age-related diseases. Despite a decade and a half of research, the safety and efficacy of stem cell therapy has still not been proven, experts from the US Food and...

read more

Press Release: Exopharm company spun out to commercialise a completely new type of nano-drug for regenerative medicine

A private Australian biotechnology company called Exopharm has announced its investment to bring a completely new type of drug called exosomes into local clinical trials.
Exopharm is founded and backed by Dr Ian Dixon, the Melbourne-based technology innovator behind an ASX-listed cell therapy company, the anisina anticancer drug and the Altnia Group incubator.
After more than 3 years of secret R&D, Altnia is spinning Exopharm out as a specialist company to translate the promising scientific research around exosomes into routine clinical use worldwide for regenerative medicine. Exopharm will build on its patented purification technology called LEAP to make its proprietary exomeres in large scale and at low cost.

read more